Evènements

Lyonbiopôle a organisé un séminaire international de présentation des développements technologiques des pôles de compétitivité français, en partenariat avec ces derniers et le Ministère de l'Industrie.

Lire le communiqué de presse

Programme des interventions et fiches de présentation des projets

(cliquez sur les noms des projets pour télécharger leur présentation)

Moderator : Patrick Tricoli, Senior Director,
Partnering & Innovation, sanofi-aventis

11.00 am
Welcome Address
Daniel Bosley, State Representative and Chairman, Joint Committee on Economic
Development and Emerging Technologies

And Christa Bleyleben, Executive Director, Massachusetts Office of International Trade & Investment (MOITI), on behalf of Deval PATRICK, Governor of the Commonwealth of Massachusetts

And Bernard de Montferrand, Ambassador at large, French Ministry of Industry

11.15 am
Opening: Key assets of the French Business Attractivity
Jean-Pierre GARNIER, CEO, GSK

Genome Engineering, Central Nervous System

11.30 am
INGENIS: Meganuclease mediated genome surgery for therapeutic and industrial applications
David J.D. SOURDIVE, VP Corporate Development, CELLECTIS SA
Prove the concept of Meganuclease mediated genome surgery for therapeutic and industrial applications in bio/pharma industry

International Large Scale Facilities and Know -How
TransAl: The first primate model of Alzheimer's disease
Elee DUCONSEILLE, Project Manager, Valorisation & Innovation Department, sanofi-aventis
Translational approach against Alzheimer's disease : research of biomarkers using imaging in vivo in Primate and transgenic mice, to accelerate the identification and the development of innovative treatments.

EDITING: A new way to treat depression
Dr Dinah WEISSMANN, CEO, Biocortech
Modulation of editing is a new way to address the treatment of mood disorder. Biocortech technology allows monitored treatment via a diagnose of depression and adapted compounds

 

Infectious Diseases, Oncology, Inflammatory Diseases

01.30 pm
ADNA: Advanced Diagnostics and New Therapeutic Approaches - Focus on new therapeutic vaccines for infectious diseases and cancer
Philippe CLEUZIAT, Ph.D, ADNA Program Director, Mérieux Alliance
Jean-Yves BONNEFOY, Ph.D, VP, R&D, Transgene
The ADNA program is designed to support the development of personalized medical solutions for cancer, infectious diseases and rare genetic diseases by providing healthcare professionals with innovative biodiagnostic tools and new therapeutic approaches International Large Scale Facilities and Know-How.

GlycAb and Arronax: Generation of new radionuclides for targeted Radioimmunotherapy
Dr Jacques BARBET, Ph.D, Scientific advisor, Chelatec and CSO, GIP Arronax
Next-generation radiotherapy relies on carrying radioduclides to the target cell. This involves generating a combination of new suitable radionuclides and developing adapted target-specific bio-carriers

PRAVIC: Innovative recombinant proteins with immune modulatory and antitumor activities - Focus on recombinant enzymes
Gilles ALBERICI, Président, OPi
Tristan ROUSSELLE, CEO, Protein'eXpert
Different approaches for the treatment of virus-induced blood cancers (lymphomas, leukaemias) : First fully human anti-IL6 antibody, New generation of L-Asparaginases ans Selection of new targets for B and T lymphomas and design of fully human monoclonal antibodies

COLCATS: Discovery and validation of new druggable targets for the treatment of colorectal cancer
Jean-Baptiste PIN, CEO, Fluofarma
Combination of genomic and post-genomic "high content" approaches for the discovery of relevant drug targets in colorectal cancer, and for the identification of new chemical leads

TrKB: An original Target for novel Anticancer Drugs
Jean DEREGNAUCOURT, Vice-President, Pierre Fabre
A multi funded public-private project gathering french biocluster partners together with german and dutch contributors and aiming at developing much needed new agents acting against the tumor metastasis process

OLNORME: Occurrence of novel Ligands for a Nuclear Orphan Receptor in plant Metabolites
Jean-François MOUNEY, Chairman, GENFIT
The main challenge of this research proposal is to deorphanize well-characterized orphan nuclear receptors that are relevant targets for diseases with an inflammatory component. The search of novel ligands will be based on the screening of highly diversified library of plant metabolites established by the Bicoll group

Pre-conclusion: Competitiveness clusters, a new industrial and innovation policy in France
Alain GRIOT, Head of technological Partnerships Office, French Ministry of Industry

Key Note: American companies growing in France
Prestwick Chemicals Inc.
Paul BIKARD, CFO
Idenix Pharmaceuticals Inc.
Jean-Marc ALLAIRE, Vice-President, European Operations

03.30 pm
Closing: Key factors to successfully develop your business in France
Philippe ARCHINARD, CEO, Transgene, President of Lyonbiopôle